A new therapeutic candidate targets fatty liver disease by degrading a key enzyme
A study published in Acta Pharmacologica Sinica reports on a potential new drug, 84-B10, for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). The research indicates that 84-B10 exerts its therapeutic effect by promoting the degradation of fatty acid synthase (FASN), a critical enzyme in hepatic lipogenesis. This targeted degradation of FASN represents a novel mechanism of action aimed at reducing the pathological fat accumulation in the liver that characterizes MASLD.
Why it might matter to you: This research highlights a direct pharmacological strategy—enzyme degradation—for a prevalent metabolic disorder, moving beyond simple inhibition. For professionals focused on drug discovery and pharmacokinetics, the mechanism of promoting FASN degradation presents a distinct therapeutic avenue that could influence drug design for liver diseases. Understanding such targeted approaches is crucial for developing the next generation of small-molecule drugs with potentially improved efficacy and specificity in clinical trials.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
